Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening

BioScience Trends

Volumn 6, Issue 4, 2012, Pages 192-200

  Wang, Lulu ^a,b   Zhao, Hong ^b   Cui, Kemi ^b   Yao, Linli ^a   Ren, Min ^c   Hao, Aijun ^a   Smollen, Patrick ^b   Nie, Fang ^b   Jin, Guangxu ^b   Liu, Qian ^a   Wo, Stephenng T C ^b  

^a SHANDONG UNIVERSITY   (China)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Annotated compound library; Cell growth; Cell invasion; Glioblastoma; Screening

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BRAIN TUMOR; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; METHODOLOGY; MOLECULAR LIBRARY; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASM INVASIVENESS; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES;

EID: 84866850009     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2012.v6.4.192     Document Type: Article

References (33)

1. Azizi SA, Miyamoto C. Principles of treatment of malignant gliomas in adults: An overview. J Neurovirol. 1998; 4:204-216.
2. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW, Watts G, Trent JM, Wei JS, Giese A, Berens ME. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: A cDNA microarray analysis. J Neurooncol. 2001; 53:161-176.
3. Decaestecker C, Debeir O, Van Ham P, Kiss R. Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev. 2007; 27:149-176.
4. Henry S, Bigler S, Wang J. High throughput analysis of neural progenitor cell proliferation in adult rodent hippocampus. Biosci Trends. 2009; 3:233-238.
5. Fan F, Wood KV. Bioluminescent assays for highthroughput screening. Assay Drug Dev. Technol. 2007; 5:127-136.
6. Zhao H, Tang C, Cui K, Ang BT, Wong ST. A screening platform for glioma growth and invasion using bioluminescence imaging. Laboratory investigation. J Neurosurg. 2009; 111:238-246.
7. Justice BA, Badr NA, Felder RA. 3D cell culture opens new dimensions in cell-based assays. Drug Discov Today. 2009; 14:102-107.
8. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L, Glushko V. Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci U S A. 1986; 83:465-469.
9. Zhang JH, Chung TD, Oldenburg KR. A Simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999; 4:67-73.
10. Rajasekaran SA, Palmer LG, Quan K, Harper JF, Ball WJ Jr, Bander NH, Peralta Soler A, Rajasekaran AK. Na,K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility. Mol Biol Cell. 2001; 12:279-295.
11. Quintavalle M, Elia L, Price JH, Heynen-Genel S, Courtneidge SA. A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci Signal. 2011; 4:49.
12. Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004; 22:4779-4786.
13. Schlenska-Lange A, Knüpfer H, Lange TJ, Kiess W, Knüpfer M. Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor 1 in vitro. Anticancer Res. 2008; 28:1055-1060.
14. Yin S, Girnita A, Stromberg T, Khan Z, Andersson S, Zheng H, Ericsson C, Axelson M, Nistér M, Larsson O, Ekström TJ, Girnita L. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro oncol. 2010; 12:19-27.
15. Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel ER, Kris MG. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2003; 51:493-498.
16. Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs. 2003; 21:367-372.
17. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M; North American Brain Tumor Consortium. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol. 2003; 21:2305-2311.
18. Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2- chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000; 6:3878-3884.
19. Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, Arnold H, Gundersen G. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer. 1997; 75:1744-1752.
20. Rice WG, Hillyer CD, Harten B, Schaeffer CA, Dorminy M, Lackey DA 3rd, Kirsten E, Mendeleyev J, Buki KG, Hakam A, Rice WG. Induction of endonucleasemediated apoptosis in tumor cells by C-nitrososubstituted ligands of poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A. 1992; 89:7703-7707.
21. Lo TW, Thornalley PJ. Inhibition of proliferation of human leukaemia 60 cells by diethyl esters of glyoxalase inhibitors in vitro. Biochem Pharmacol. 1992; 44:2357-2363.
22. Townsend DM, Tew KD. The role of glutathione-Stransferase in anti-cancer drug resistance. Oncogene. 2003; 22:7369-7375.
23. Juillerat-Jeanneret L, Bernasconi CC, Bricod C, Gros S, Trepey S, Benhattar J, Janzer RC. Heterogeneity of human glioblastoma: Glutathione-S-transferase and methylguanine-methyltransferase. Cancer Invest. 2008; 26:597-609.
24. Liou SF, Lin HH, Liang JC, Chen IJ, Yeh JL. Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis. Toxicology. 2009; 256:13-24.
25. Zilles K, Qü M, Schleicher A. Regional distribution and heterogeneity of alpha-adrenoceptors in the rat and human central nervous system. J Hirnforsch. 1993; 34:123-132.
26. Ning YM, Sánchez ER. Evidence for a functional interaction between calmodulin and the glucocorticoid receptor. Biochem Biophys Res Commun. 1995; 208:48-54.
27. Lee GL, Hait WN. Inhibition of growth of C6 astrocytoma cells by inhibitors of calmodulin. Life Sci. 1985; 36:347-354.
28. Beil W, Hackbarth I, Sewing KF. Mechanism of gastric antisecretory effect of SCH 28080. Br J Pharmacol. 1986; 88:19-23.
29. +-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem. 1987; 262:2077-2084.
30. + ATPase inhibitors cause relaxation of guinea pig and human airway smooth muscle in vitro. J Pharmacol Exp Ther. 1996; 276:897-903.
31. Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2005; 2:3-14.
32. Groothuis DR. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro Oncol. 2000; 2:45-59.
33. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ. 2004; 11:737-746.